296 related articles for article (PubMed ID: 9925527)
1. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
2. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Jones ME; Sahm DF; Martin N; Scheuring S; Heisig P; Thornsberry C; Köhrer K; Schmitz FJ
Antimicrob Agents Chemother; 2000 Feb; 44(2):462-6. PubMed ID: 10639387
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
5. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
[TBL] [Abstract][Full Text] [Related]
6. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
Varon E; Janoir C; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
[TBL] [Abstract][Full Text] [Related]
7. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
[TBL] [Abstract][Full Text] [Related]
8. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
9. Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
Zheng X; Johnson C; Lu Y; Yanagihara R; Hollingshead S; Crain M; Benjamin W; Waites KB
Int J Antimicrob Agents; 2001 Oct; 18(4):373-8. PubMed ID: 11691571
[TBL] [Abstract][Full Text] [Related]
10. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
Taba H; Kusano N
Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
[TBL] [Abstract][Full Text] [Related]
11. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
[TBL] [Abstract][Full Text] [Related]
12. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.
Davies TA; Evangelista A; Pfleger S; Bush K; Sahm DF; Goldschmidt R
Antimicrob Agents Chemother; 2002 Jan; 46(1):119-24. PubMed ID: 11751121
[TBL] [Abstract][Full Text] [Related]
14. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci.
Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I
J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428
[TBL] [Abstract][Full Text] [Related]
16. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
Ling JM; Chan EW; Lam AW; Cheng AF
Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
[TBL] [Abstract][Full Text] [Related]
17. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Tankovic J; Perichon B; Duval J; Courvalin P
Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
[TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
González I; Georgiou M; Alcaide F; Balas D; Liñares J; de la Campa AG
Antimicrob Agents Chemother; 1998 Nov; 42(11):2792-8. PubMed ID: 9797205
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
Bast DJ; Low DE; Duncan CL; Kilburn L; Mandell LA; Davidson RJ; de Azavedo JC
Antimicrob Agents Chemother; 2000 Nov; 44(11):3049-54. PubMed ID: 11036021
[TBL] [Abstract][Full Text] [Related]
20. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Shultz TR; Tapsall JW; White PA
Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
